Evidence map›Paper›PMID 37180648›Full record

ArticleTranslational cancer research2023

Dexi Wang, Yun Sun, Qiaoyun Liu, Chenyu Ye, Shengjun Zhao, Haiying Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Biochemistry and biophysics reports · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dexi WangGraduate School, the Fourth Clinical College of Xinjiang Medical University, Urumqi, China.
Yun SunDepartment of Traditional Chinese Medicine, the Traditional Chinese Medicine College of Xinjiang Medical University, Urumqi, China.
Qiaoyun LiuGraduate School, the Fourth Clinical College of Xinjiang Medical University, Urumqi, China.
Chenyu YeGraduate School, the Fourth Clinical College of Xinjiang Medical University, Urumqi, China.
Shengjun ZhaoDepartment of Pharmacy, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi, China.
Haiying ZhangDepartment of Pharmacy, Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University, Urumqi, China.
Xinjiang Medical University · CNXinjiang Technical Institute of Physics & Chemistry · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Based on a review of the literature and previous experiments conducted by our research group, the active compounds of Results: Final results indicated that the active compounds include Farnesiferol C, Assafoetidin, Lehmannolone, Badrakemone, etc. The identified core target genes were Conclusions: This study revealed that

Indexed as

bioinformatics analysisFerula sinkiangensis (F. sinkiangensis)gastric cancermolecular dockingnetwork pharmacologyvitro experiment

Identifiers

PMID37180648
PMCPMC10174895
OpenAlexW4367314241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.